Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TriPath Imaging, Inc.

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement is submitted to FDA covering use of the AutoPap automated primary Pap smear slide screening system with cytology samples prepared using the Prep automated, liquid-based Pap smear sample preparation system. TriPath is the new name for the recent combination of Prep system developer AutoCyte and AutoPap maker NeoPath under a June merger completed Oct. 1 (1"The Gray Sheet" June 14, p. 15). The Prep system was approved June 17 to replace conventional Pap smear preparation in primary screening for cervical cancer but not specifically for use with AutoPap, which was approved for initial screening of conventional slides in May 1998

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel